The development of immune checkpoint inhibitors [monoclonal antibodies targeting
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD …

Antineoplastic agents that use the immune system have revolutionized cancer treatment.
Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that …

Background Cutaneous adverse events are common with programmed death 1 (PD-
1)/programmed death ligand 1 (PD-L1) inhibitors. However, the nature of the specific …

Checkpoint inhibitors (CPIs) are monoclonal antibodies which, by disrupting interactions of
immune checkpoint molecules with their ligands, block regulatory immune signals otherwise …

Immune checkpoint inhibitors (ICPIs) have emerged as a frontline treatment for a growing list
of malignancies. Disruption of the negative regulatory immune checkpoints by ICPIs has …

Paraneoplastic autoimmune multiorgan syndrome (PAMS) is characterized by a
heterogenous group of signs and symptoms including severe desquamative stomatitis, a …

Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when
immune responses are activated. Although immune checkpoint inhibitors (CPIs) are …

Immune checkpoint inhibitors (ICIs) reinvigorate anti-tumor immune responses by disrupting
co-inhibitory immune checkpoint molecules such as programmed cell death 1 (PD-1) and …

Immune check point inhibitor (CPI) therapy has revolutionized treatment paradigms for
several cancers, but at the cost of triggering a diverse spectrum of immune-mediated injury …

Grover disease (GD) is a benign eruption that causes a papulovesicular rash on the trunk
and proximal extremities. It often resolves spontaneously but can follow a more chronic and …